Stockreport

Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201 [Yahoo! Finance]

Pyxis Oncology, Inc.  (PYXS) 
PDF - PYX-201 is a novel first-in-concept antibody-drug conjugate (ADC) where significant RECIST responses were seen in head and neck squamous cell carcinoma (HNSCC) with a [Read more]